{"entity":{"id":"nct04159818","kind":"trial","name":"Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients","aka":["TONIC-2"],"tldr":"A phase 2 trial of nivolumab and cisplatin in triple-negative breast cancer, run by The Netherlands Cancer Institute, now recruiting.","summary":"Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients is a phase 2, randomised interventional study registered as NCT04159818 by The Netherlands Cancer Institute, with a registry enrolment figure of 52 participants, started 2020-02-21 and due to reach its primary completion in 2022-12-15. Interventions recorded: Nivolumab; Cisplatin; Low dose doxorubicin. Conditions listed: Metastatic Breast Cancer. Triple-negative eligibility wording from the registry: \"* Metastatic or incurable locally advanced triple negative breast cancer (ER \\< 10%, HER2 IHC 0,1+ or 2+ with no amplification)\". Sites: Netherlands. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT04159818","url":"https://clinicaltrials.gov/study/NCT04159818"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-metastatic"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["nivolumab","cisplatin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04159818","phase":"2","setting":"Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients: the TONIC-2 Trial","sponsor":"The Netherlands Cancer Institute","enrolled":52,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04159818/","neighbours":{"cancer":[{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}